17ß-estradiol (1 mg) i drospirenon (2 mg) w terapii hormonalnej okresu pomenopauzalnego
Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviatingclimacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, andhas a positive influence on lipid profile, carbohydrate metabolism, arterial pressure a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2010-02-01
|
| Series: | Menopause Review |
| Subjects: | |
| Online Access: | http://www.termedia.pl/17ss-estradiol-1-mg-i-drospirenon-2-mg-w-terapii-hormonalnej-okresu-pomenopauzalnego,4,14196,1,0.html |